Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 October 2021 | Story Eugene Seegers | Photo Jolandi Griesel
Dr Arnelle Mostert receives the Vice-Chancellor’s Award for excellence in learning and teaching from the Vice-Rector: Academic, Dr Engela van Staden, at the annual Learning and Teaching Awards ceremony held in Bloemfontein on 13 October 2021.

The annual Learning and Teaching conference was held virtually by the Centre for Teaching and Learning from 13 to 15 September 2021. The conference, with the theme Quality and Innovation for a New Blended Learning Future, culminated in the annual UFS Learning and Teaching Awards, held on the Bloemfontein Campus on 13 October.

Highlights from Learning and Teaching Awards

This year, the Centre for Teaching and Learning recognised various academic staff members in different learning and teaching categories during the annual Learning and Teaching Awards ceremony. The categories included innovation in learning and teaching (curriculum design / assessment / student engagement / technology-enhanced learning and teaching); research in learning and teaching (novice and advanced); as well as the Vice-Chancellor’s Award. The Vice-Chancellor’s Award acknowledges all-round excellence in the field of learning and teaching.

Dr Arnelle Mostert from the Faculty of Health Sciences, who brought home the Vice-Chancellor’s Award, says, “To win this award has been a dream of mine for a very long time. I am so excited and grateful, as this prize is the culmination of years of dedication and hard work. Excellence in teaching and learning, in my eyes, lies in the small acts we do daily: Improving one lecture at a time, one word of encouragement, helping one student understand a concept, and most of all, touching one heart at a time with kindness and compassion. These small acts create a ripple effect in many peoples’ lives, as the students we teach can touch the lives of many others."

Not only have academic staff been rewarded, but the most valued professional award recognised the contribution of academic support professionals towards the advancement of learning and teaching at the institution and acknowledged dedication, innovation, and excellence in the support sphere. 

Gugu Tiroyabone, winner of the Most Valued Professional award, says of this accolade, “For me, this recognition affirms the commitment of the UFS to Goal 1 of its Strategic Plan 2018-2022: To improve student success and well-being. Reflecting on the past 19 months, a changing educational climate, and an evolving learning and teaching landscape, I appreciate how the new challenges have helped us grow as an institution, both as staff and as students. I am extremely thankful to work alongside a resilient team that is committed to holistic student success both inside and outside the classroom.”

For the first time, the Departmental Award for learning and teaching was bestowed on the School of Accounting (Bloemfontein Campus) and the School of Education Studies (Qwaqwa Campus). These two departments have shown great commitment and involvement in improving learning and teaching under the leadership of Prof Frans Prinsloo and Dr Bekithemba Dube.

This year, the best Qwaqwa and the best Bloemfontein conference paper presentations each received an award. The awards were won by Dr Brian Sibanda (CTL, Qwaqwa Campus) for his paper Practicing decoloniality in English Academic Literacies, and Dr Rick de Villiers (The Humanities, Bloemfontein Campus) for his presentation on Close reading at a distance: Making remote learning intimate and intensive.


Highlights from conference

Day 1: The conference was opened by the international keynote speaker, Dr Carl S Moore, Assistant Chief Academic Officer at the University of the District of Columbia, who gave the presentation Access to Learning. This presentation highlighted the role of online and blended learning within the future of higher education.

Day 2: Guest keynote speaker, Dr Noluthando Toni, Director of Teaching Development at Nelson Mandela University, presented Towards re-imagined blended learning and teaching: Heeding student voices and participation to bolster education practices. Dr Toni’s presentation focused on contextualising the new blended learning and teaching environment within South Africa, and shared experiences from her institution during their remote learning and teaching strategy (2020/21).

Day 3: The guest keynote speakers, Dr Adriana Botha (educational psychologist and senior educational consultant: Blackboard) and Dennis Nevels, presented the paper From Conventional to Online Assessment – Rethink and Innovate, in which they focused on providing academic staff with innovative practices and ideas around online assessment.

Throughout the three days, UFS academic and support staff members shared quality learning and teaching projects and innovations through academic papers in different conference tracks.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept